Bottom line: At this point, there is no clear evidence that GLP-1 agonists cause depression or suicidal behavior in the average patient, but there are signals that merit caution
SpringerLink Avraham SA, et al
[25:45] B Yeah
At Intra-V (with locations in Katy, TX and The Woodlands, TX ), we see this trend for what it really is: not a social media hack, but a form of personalized dosing carefully guided by a clinicianfocused on tolerability, consistency, and long-term metabolic improvement
Low muscle tone, developmental delays, cognitive disabilities, and behavioral challenges are also common features of the disorder
The dataset covered more than 142,000 patients with type 2 diabetes or obesity